CARY, N.C.--(BUSINESS WIRE)--Biologics, an integrated oncology services company, is pleased to announce that Biologics has been selected as a specialty pharmacy authorized to dispense Ibrance (palbociclib). Ibrance was approved by the U.S. Food and Drug Administration on February 3, 2015 to be used in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease.
Help employers find you! Check out all the jobs and post your resume.
